InvestSMART

Neuren Pharmaceuticals Limited (ASX:NEU)

ALERT: Price-sensitive ASX Announcement for NEU
Current share price for NEU : $17.050 -2.09 (-10.92%)+
Announcement
Release
19 Jan 2026 9:10AM
Price at Release
$19.140
Full Release
download
Summary
Neuren Pharmaceuticals Limited (NEU) responded to an ASX Aware Letter concerning an announcement about the projected global net sales of DAYBUE, a drug licensed to Acadia Pharmaceuticals Inc., to reach approximately US$700 million by 2028. The projection, deemed potentially impactful on NEU's securities, resulted in a significant share price increase following the announcement. NEU confirmed the projection's reasonableness, based on ACAD's disclosures and internal financial assessments, and stated compliance with ASX Listing Rules, particularly Rule 3.1, governing immediate disclosure requirements. NEU's board authorized the responses, ensuring alignment with continuous disclosure policy.
Key Points
  • NEU's announcement projected DAYBUE's global net sales to reach ~US$700m in 2028.
  • The announcement led to a share price increase from $19.61 to $21.04.
  • NEU confirmed the projection's material effect on securities' value.
  • The projection's reasonableness was supported by ACAD's disclosures and NEU's internal models.
  • NEU ensured compliance with ASX Listing Rules and confirmed immediate disclosure.
  • NEU's Board authorized responses in line with continuous disclosure policy.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.